The Platinum-Based Treatments for Advanced Non-small Cell Lung Cancer: is Excision Repair Cross-Complementation Group 1 Low/Negative Expression Better Than Its High/Positive Expression? A Metaanalysis

Zhang Jie,Chen SuFeng,Liu Shilei,Luketich James,Gibson Michael,Wang Rui,Chen Haiquan

DOI: https://doi.org/10.1378/chest.10678

IF: 9.6

2010-01-01

Chest

Abstract:PURPOSE: The predictive value of excision repair cross-complementation group 1 (ERCC1) for prognosis and sensitivity to platinum-based chemotherapy in patients with non-small cell lung cancer (NSCLC) remains controversial. This meta-analysis was performed to provide an assessment of whether expression variations of ERCC1 are associated with objective response and median survival in patients with advanced NSCLC treated with platinum-based chemotherapy.